GEP20247587B - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
GEP20247587B
GEP20247587B GEAP201715070A GEAP2017015070A GEP20247587B GE P20247587 B GEP20247587 B GE P20247587B GE AP201715070 A GEAP201715070 A GE AP201715070A GE AP2017015070 A GEAP2017015070 A GE AP2017015070A GE P20247587 B GEP20247587 B GE P20247587B
Authority
GE
Georgia
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
GEAP201715070A
Inventor
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Tom Dudler
Nigel John Brunskill
Original Assignee
Univ Leicester
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Univ Leicester, Omeros Corp filed Critical Univ Leicester
Publication of GEP20247587B publication Critical patent/GEP20247587B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

РЕФЕРАТ В одном из аспектов изобретение относится к способам уменьшения протеинурии у человека, страдающего или подверженного риску развития иммуноглобулин А нефропатии (IgAN). Способы включают этап введения нуждающемуся в этом субъекту количества ингибирующего MASP-2 антитела, эффективного для подавления MASP-2-зависимой активации комплемента.
GEAP201715070A 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy GEP20247587B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
GEP20247587B true GEP20247587B (en) 2024-01-25

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201715070A GEP20247587B (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (18)

Country Link
EP (1) EP3525798A4 (en)
JP (1) JP6893554B2 (en)
KR (1) KR102348939B1 (en)
CN (2) CN110177557A (en)
AU (1) AU2017342428B2 (en)
BR (1) BR112019007426A2 (en)
CA (2) CA3039927C (en)
CL (2) CL2019000909A1 (en)
GE (1) GEP20247587B (en)
IL (1) IL265981A (en)
JO (1) JOP20190068A1 (en)
MA (1) MA46541A (en)
MX (1) MX2019004074A (en)
PH (1) PH12019500711A1 (en)
SG (1) SG11201902941UA (en)
UA (1) UA126908C2 (en)
WO (1) WO2018071701A1 (en)
ZA (1) ZA201902933B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (en) * 2020-03-19 2020-07-17 长春市儿童医院 Glomerular lobular nephropathy modeling method
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
CN117016486A (en) * 2023-07-20 2023-11-10 澎立生物医药技术(上海)股份有限公司 Animal model construction method for IgA nephropathy combined membranous nephropathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Antibodies to masp-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
BR112012008970A2 (en) * 2009-10-16 2019-12-10 Omeros Corp use of a composition and composition
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
MX355648B (en) 2011-04-08 2018-04-26 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation.
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUE049154T2 (en) * 2011-05-04 2020-09-28 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
WO2014144542A2 (en) * 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
DK3057993T3 (en) * 2013-10-17 2020-11-16 Omeros Corp Method for Treating Conditions Associated with MASP-2 Dependent Complement
SG11201805695SA (en) * 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
ZA201902933B (en) 2023-05-31
CN110177557A (en) 2019-08-27
EP3525798A4 (en) 2020-07-08
JP6893554B2 (en) 2021-06-23
PH12019500711A1 (en) 2019-11-18
KR20190063475A (en) 2019-06-07
BR112019007426A2 (en) 2019-07-02
JP2019534271A (en) 2019-11-28
AU2017342428B2 (en) 2021-02-04
KR102348939B1 (en) 2022-01-12
MX2019004074A (en) 2019-06-10
UA126908C2 (en) 2023-02-22
WO2018071701A1 (en) 2018-04-19
EP3525798A1 (en) 2019-08-21
CA3039927A1 (en) 2018-04-19
CA3039927C (en) 2023-10-10
AU2017342428A1 (en) 2019-05-23
IL265981A (en) 2019-06-30
SG11201902941UA (en) 2019-05-30
JOP20190068A1 (en) 2019-04-01
MA46541A (en) 2019-08-21
NZ753260A (en) 2021-11-26
CA3210384A1 (en) 2018-04-19
CL2019000909A1 (en) 2019-06-14
CL2019003485A1 (en) 2020-04-13
CN116726163A (en) 2023-09-12

Similar Documents

Publication Publication Date Title
MX2021006237A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof.
GB201804136D0 (en) Providing out-of-band verification for blockchain transactions
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
KR20180084886A (en) Beverage maker, system with beverage maker, method for operating same
EP3280200A4 (en) Method for performing ranging related operation in wireless communication system
IL259348B (en) Headtracking for parametric binaural output system and method
EP3136169A4 (en) Light source system, and projection system and method
DK3131585T3 (en) MULTIDENTATE, BY-FUNCTIONAL CHELATING AGENTS FOR RADIONUCLID COMPLEX FORMATION IN DIAGNOSTICS AND THERAPY
SG11201704160XA (en) Antibodies, uses & methods
EP3191973A4 (en) Technologies for proxy-based multi-threaded message passing communication
EP3157294A4 (en) Method for controlling timing advance for direct communication between terminals in wireless communication system, and apparatus therefor
EP3115827A4 (en) 3d conversion lens, 3d glasses, and control method therefor
MX2020007742A (en) Processes for preparing fluoroketolides.
GEP20247587B (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
KR101556994B9 (en) Faucet establishing jig
SG11202002314WA (en) Polishing solution, polishing solution set, and polishing method
DK2993275T3 (en) PUMP STATION, WASTE SYSTEM AND PROCEDURE FOR TRANSPORTING WASTE
EA201700060A1 (en) THERAPEUTIC TOOL FOR CERATO-CONJUNCTIVE DISORDERS
EP3218826A4 (en) System for cross-host, multi-thread session alignment
GB201504983D0 (en) Authentication for mobile transactions
KR101860073B9 (en) Faucet establishing jig
MX2017003728A (en) Flavor enhancement system.
IL274432B (en) Headtracking for parametric binaural output system and method
HUP1600486A2 (en) Smart mobile cabinet, especially saddle cabinet
GB201601412D0 (en) Financial transaction lifestyle quality scoring system